Your dr is a bit behind the times. There is now no need to limit HRT to any length of time . The risks that were found in 2002 have been shown to be exaggerated and discredited. Very few GPs seem up to date with this.
How old are you and have you come off HRT slowly or immediately? If anyone stops they should gradually come off it over 3-6 months by reducing the dose.
You may be suffering aches and pains because of the rapid loss of oestrogen. if your dr wants you to sign a disclaimer- to cover them against you suing if you get side effects- then just do it. All it means is that you have been made aware of the risks and have made an informed decision to stay on HRT.
Have a read of these guidelines from the BMS
BMS Consensus Statements: Summary & Practice Points
Title: Hormone Replacement Therapy
Article: » print this
Managing the Menopause
British Menopause Society Council Consensus Statement on Hormone Replacement Therapy
Summary
The British Menopause Society Council aims to aid health professionals to inform and advise women about the menopause. This guidance refers to estrogen- based hormone replacement therapy (HRT) and tibolone, which is classified in the British National Formulary as HRT. Treatment choice should be based on up to date information and targeted to individual women's needs. HRT still offers the potential for benefit to outweigh harm, providing the appropriate regimen has been instigated in terms of dose, route and combination for a valid clinical indication.
23 May 2013
Summary practice points
The decision whether to use HRT should be made by each woman having been given sufficient information by her health professional to make a fully informed choice
The HRT dosage, regimen and duration should be individualised, with annual evaluation of pros and cons.
Arbitrary limits should not be placed on the duration of usage of HRT; if symptoms persist, the benefits of hormone therapy usually outweigh the risks
HRT prescribed before the age of 60 has a favourable benefit / risk profile.
It is imperative that women with premature ovarian insufficiency are encouraged to use HRT at least until the average age of the menopause.
If HRT is to be used in women over 60 years of age, lower doses should be started, preferably with a transdermal route of administration.
It is imperative that in our ageing population research and development of increasingly sophisticated hormonal preparations should continue to maximise benefits and minimise side effects and risks.
This will optimise quality of life and facilitate the primary prevention of long term conditions which create a personal, social and economic burden.